MC-VC-PABC-DNA31 is a drug-linker conjugate designed for Antibody-Drug Conjugates (ADC) that demonstrates potent antitumor activity. It employs DNA31, an effective inhibitor of RNA polymerase, connected through the MC-VC-PABC ADC linker.
dmDNA31 is a rifamycin antibiotic that can inhibit the DNA-dependent RNA polymerase of bacteria and has strong bactericidal activity against Staphylococcus aureus.
MC-Val-Cit-PAB-dimethylDNA31 is a drug-linker conjugate employed in antibody-drug conjugates (ADCs) that exhibits robust antitumor efficacy. This conjugate utilizes the ADC linker, MC-Val-Cit-PAB, to link to the potent antitumor agent dimethylDNA31. Notably, dimethylDNA31 also demonstrates significant bactericidal activity against both persister and stationary-phase Staphylococcus aureus.
Seclidemstat mesylate (SP-2577) is a highly effective and reversible inhibitor of KDM1A (LSD1), with a Ki of 31 nM and an IC 50 of 13 nM. It demonstrates significant potential in promoting antitumor immunity in switch sucrose nonfermentable (SWI SNF) complex mutated ovarian cancer, while also exhibiting inhibitory effects on virus production, viral DNA replication, and late gene expression. Seclidemstat mesylate is a valuable tool for studying Ewing Sarcoma in research settings.